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Background:  In  the United  States,  live  attenuated  inﬂuenza  vaccine  (LAIV)  was  initially  approved  for  use
in  individuals  aged  5–49  years  in  2003,  which  was  extended  to individuals  aged 2–49 years  in  2007.  At
that  time,  a postlicensure  commitment  was  made  to  describe  the  safety  of  LAIV  within  a  cohort  of  eligible
children  aged  2–5  years.
Methods:  A  prospective  observational  postmarketing  study  was  conducted  to evaluate  the  safety  of  LAIV.
Rates  of medically  attended  events  (MAEs)  and  serious  adverse  events  (SAEs)  in eligible  children  aged
24–59  months  receiving  LAIV  as  part  of  routine  care  from  October  2007  to  March  2010  were  com-
pared  with  rates  in a within-cohort  self-control,  as  well  as  matched  unvaccinated  and  matched  trivalent
inactivated  inﬂuenza  vaccine  (TIV)-vaccinated  controls.  Children  with  asthma  and  other  high-risk  medi-
cal conditions  before  vaccination  were  excluded.  All  MAEs  and  SAEs  through  42  days  postvaccination  and
all hospitalizations  and  deaths  through  6  months  postvaccination  were  analyzed.  Statistical  signiﬁcance
was  declared  without  multiplicity  adjustment.
Results: A  total  of  28,226  unique  LAIV  recipients  were  matched  with  similar  numbers  of  TIV-vaccinated
and  unvaccinated  children.  Of  4696  MAE  incidence  rate  comparisons,  83  (1.8%)  were  statistically  signif-
icantly  higher  and  221  (4.7%)  were  statistically  signiﬁcantly  lower  in LAIV  recipients  versus  controls.  No
pattern of MAE  rate  differences  suggested  a safety  signal  with  LAIV.  Asthma/wheezing  MAEs  were  not
statistically  increased  in  LAIV  recipients.  No  anaphylaxis  events  occurred  within  3 days  postvaccination.
Rates  of SAEs  were  similar  between  LAIV  and  control  groups.
Conclusions:  Results  of this  postlicensure  evaluation  of  LAIV  safety  in  US  children  are  consistent  with
preapproval  clinical  studies  and  Vaccine  Adverse  Event  Reporting  System  reports,  both  of which  demon-
strated  no  signiﬁcant  increase  in asthma/wheezing  events  or  other  adverse  outcomes  among  eligible
children  aged  24–59  months  who  received  LAIV.Abbreviations: AGI, acute gastrointestinal tract; ART, acute respiratory tract; AW,
sthma and wheezing; ED, emergency department; FU, follow-up; HR, hazard ratio;
P, Kaiser Permanente; LAIV, live attenuated inﬂuenza vaccine; MAE, medically
ttended event; PSDI, prespeciﬁed diagnoses of interest; RAD, reactive airway dis-
ase; RR, relative risk; RSV, respiratory syncytial virus; SAE, serious adverse event;
BI, systemic bacterial infections; SOB, shortness of breath; TIV, injectable trivalent
nactivated inﬂuenza vaccine; URI, upper respiratory tract infection; WTI, wild-type
nﬂuenza.
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1. Introduction
The intranasal Ann Arbor strain live attenuated inﬂuenza vac-
cine (LAIV; MedImmune, LLC, Gaithersburg, MD) was initially
licensed in 2003 for use in eligible individuals aged 5–49 years.
Postlicensure studies revealed no safety concerns in this age
range [1,2]. In 2003, LAIV was not approved for use in chil-
dren younger than 5 years because 1 study noted an increase in
wheezing events in young children [3].  A subsequent prospective
study demonstrated an increase in medically attended wheezing in
LAIV-vaccinated children aged <24 months, but no increase in LAIV-
vaccinated children ≥24 months [4,5]. Based on this study, in 2007,
Open access under CC BY-NC-ND license.the approval of LAIV was expanded to include children aged 24–59
months [6].  In the US, LAIV is recommended for use in children
in this age group without underlying high-risk medical conditions
(e.g. asthma, diabetes, immunocompromise, etc.) as well as those
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Table  1
Summary of safety analyses.
Event Postvaccination period, d Clinical setting
Anaphylaxis, urticaria 3 Clinic, ED, hospital
Individual MAEs 21a and 42 Clinic, ED, hospital
SAEs 21 and 42 All
PSDIs  21, 42 and 180b All
Hospitalizations and deaths for all causes 21, 42 and 180 Hospital, anyc
Hospitalizations and deaths for rare events potentially related to wild-type inﬂuenza 180 Hospital, any
ED = emergency department; MAE  = medically attended event; PSDI = prespeciﬁed diagnoses of interest; SAE = serious adverse event.
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A total of 28,226 unique subjects 24–59 months of age, includinga The analysis period for the within-cohort group was for 21-day outcomes only.
b Asthma and wheezing events only.
c Deaths were assessed in any setting.
ithout an episode of wheezing in the 12 months prior to vaccina-
ion [7].  This study was designed to conduct a broad assessment of
afety, evaluating all events and prespeciﬁed events in this younger
ge group.
. Material and methods
.1. Study design
The prospective observational study collected data from Kaiser
ermanente (KP) health plan databases of participants in north-
rn California from October 2007 to March 2010; study design
nd analysis were similar to previous safety studies of LAIV using
P data in older children and adults 5–49 years of age [1,2]. Sub-
ects were given LAIV in their usual medical clinics, under routine
onditions. Screening for underlying medical conditions and vacci-
ation decisions were made by the patient and medical provider.
he safety of LAIV was assessed by comparing the rates of medically
ttended events (MAEs) in LAIV recipients to 3 nonrandomized con-
rol groups. MAEs included all medical diagnoses associated with a
edical encounter. In addition, the study analyzed serious adverse
vents (SAEs), anaphylaxis, urticaria, asthma, wheezing, prespeci-
ed diagnoses of interest (PSDI), and rare events potentially related
o wild-type inﬂuenza (WTI). The protocol was approved by the
orthern California KP institutional review board.
.2. Study populations
Approximately 25,000 children aged 24–59 months immunized
ith LAIV as part of routine clinical practice were identiﬁed through
P immunization registries. Study subjects with high-risk under-
ying medical conditions such as cancer, organ transplantation,
iabetes, blood disorders, kidney disorders, and cardiopulmonary
isorders (for whom LAIV was not recommended) were identiﬁed
ia health care databases and excluded from all analysis cohorts
1,2]. Vaccination with the 2009 monovalent H1N1 vaccine was
etermined, but no exclusions or adjustments were made.
Three nonrandomized control groups were identiﬁed for
omparison: a within-cohort (ie, self-control) control, matched
oncurrent unvaccinated controls, and matched concurrent triva-
ent inactivated inﬂuenza vaccine (TIV)-vaccinated controls. The
ithin-cohort analysis was a self-controlled risk-interval analysis
ased on event rates in different time periods after vaccina-
ion [1,2,8].  Risk intervals of 0–3 and 0–21 days postvaccination
ere compared with reference intervals from 4 to 42 days post-
accination and 22–42 days postvaccination, respectively. In the
respeciﬁed analysis, the 3 control groups were considered of equal
mportance. Frequency matching was used to identify cohorts with
imilar age (by each month of age) and geographic distributions.
nvaccinated controls were selected from KP membership; the
ndex date for calculating risk intervals was the date the matchedLAIV recipient was  vaccinated. TIV-vaccinated controls were vacci-
nated during the same month as the reference LAIV recipient
2.3. Outcome measures
Medically attended adverse events were collected from clinic
visits, emergency department (ED) visits, and hospital admissions,
as described [1,2]. Consistent with a prior study of LAIV safety con-
ducted by KP [3],  MAEs hypothesized to be potentially causally
related to vaccination were grouped as PSDI, and included acute
respiratory tract (ART) events, acute gastrointestinal tract (AGI)
events, asthma and wheezing (AW) events, systemic bacterial
infections (SBIs), and rare diagnoses potentially related to WTI. AW
was  a subset of ART and was  followed up for 180 days versus 42 days
for other PSDIs. SAEs were identiﬁed 0–42 days postvaccination and
reported regardless of potential association with LAIV, which was
determined by KP staff based on time postvaccination and biologi-
cal plausibility. Individual chart reviews were performed post hoc
for selected outcomes of interest to conﬁrm speciﬁc diagnoses.
Event rates were calculated per 1000 person-months using a Cox
proportional hazard model. Counting process style of data input
was  implemented to control for seasonal effects. The counting pro-
cess style of data input used start date and stop date or event date
as the input to proportional hazard Cox model so that the seasonal
difference in background rates were adjusted by using calendar
time intervals. Sex and healthcare utilization (0–1 vs. ≥2 visits in
prior 12 months) were included as covariates in the model. For each
incidence rate comparison, a rate ratio was  calculated. Rate com-
parisons were made for each period (3, 21, 42, or 180 days), age
group (24–35 months, 36–59 months, all ages), setting (clinic, hos-
pital, ED), and dose number. For MAEs occurring in the hospital, any
duration of inpatient hospitalization was counted (Table 1). Statis-
tical signiﬁcance was based on the exact 95% CI or the CI constructed
from the Cox proportional model. When the control group had zero
events, the relative risk or the hazard ratio was not estimable due
to a zero value in the denominator.
For the analysis of AW events, the term “asthma/reactive airway
disease (RAD)” encompassed the individual diagnoses of asthma,
cough variant asthma, and exercise-induced asthma; the term
“wheezing/shortness of breath (SOB)” included the diagnoses of
wheezing and dyspnea/SOB. Detailed methods pertaining to event
rates and the determination of statistical signiﬁcance have been
previously described [1,2]. Post hoc analyses to adjust for multi-
plicity were conducted using the Bonferroni method.
3. Results8126 subjects 24–35 months, were vaccinated with 33,443 doses
of LAIV during 3 study seasons; 27,937 unique TIV recipients, and
25,981 unique unvaccinated subjects were used as matched con-
trols. Subject characteristics are summarized in Table 2.
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Table  2
Characteristics of subjects receiving vaccine doses in all analyses.
Subject or dose characteristic,a n (%) LAIV doses
(n = 33,443)
Unvaccinated controls
(n = 28,766)
TIV controls
(n = 30,815)
Age, months
24–35 8655 (25.9) 7350 (25.6) 8184 (26.6)
36–59  24,788 (74.1) 21,416 (74.5) 22,631 (73.4)
Sex
Male  16,121 (48.2) 14,574 (50.7) 15,634 (50.7)
Female 17,322 (51.8) 14,192 (49.3) 15,181 (49.3)
Vaccine dose
1 32,261 (96.5) 28,766 (100) 30,815 (100)
2  1182 (3.5) NA NA
Utilization
High  (2+ visits) 11,813 (35.3) 9416 (32.7) 12,069 (39.2)
Low  (0 or 1 visit) 21,630 (64.7) 19,350 (67.3) 18,746 (60.8)
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a Counts are for all (nonunique) recipients of all (ﬁrst and second doses) LAIV dos
.1. Serious adverse events through 42 days postvaccination and
eaths
No deaths occurred among LAIV-vaccinated children. Thirty
AEs within 42 days postvaccination were reported in 29 sub-
ects, and occurred at an incidence rate of 0.91, 1.14, and 0.62 per
000 person-months in LAIV recipients, TIV recipients, and those
nvaccinated, respectively. All SAEs were diagnosed in the hospi-
al setting. Primary diagnoses occurring more than once included
rauma (n = 4), pneumonia (n = 4), dehydration (n = 3), congenital
nomaly (n = 2), and urinary tract infection (n = 2). Rates of SAEs
verall and by speciﬁc diagnosis were not signiﬁcantly higher or
ower in LAIV recipients relative to controls in any comparison.Of the SAEs occurring within 42 days postvaccination, only
 events were considered possibly related to LAIV. A 4-year-old
oy developed fever 3 days postvaccination; a chest radiograph
evealed right middle lobe inﬁltrate concomitant with positive test
ig. 1. Statistically signiﬁcant differences in individual MAEs in LAIV recipients 24–35, 3
ue  to pandemic H1N1 (see Discussion). FU = follow-up; MAE  = medically attended event;
RI  = upper respiratory tract infection.
ndividual medically attended events (MAEs) are grouped by organ class and medical term 
ows.  Columns represent individual analyses which are organized by comparison group 
ocation (clinic, emergency department [ED], hospital [Hosp]), and time interval (21 da
igher  rate after live attenuated inﬂuenza vaccine (LAIV) are coded orange and those occ
nalysis  (self-control) columns are fewer in number because this analysis was performed
accination are not included in the ﬁgure. No events after a second dose were statistically
igniﬁcant before the adjustment for multiple comparisons.d all (nonunique) TIV recipients and unvaccinated controls.
for respiratory syncytial virus (RSV). The subject recovered in full.
A 31-month-old boy developed abdominal pain the same day after
vaccination and was  evaluated in the ED the following day. The
subject was hospitalized and diagnosed with intussusception and
viral infection; surgical reduction of intussusception without bowel
resection was performed. The subject recovered completely.
3.2. Hospitalizations through 180 days postvaccination
There were 107 hospitalizations in 102 subjects within 180 days
of LAIV vaccination. Most common ﬁrst diagnoses included trauma
(n = 15), pneumonia (n = 10), dehydration (n = 7), epilepsy (n = 4),
and urinary tract infection (n = 4). Events in the hospital setting
that were signiﬁcantly increased in LAIV recipients versus unvacci-
nated included sleep apnea (n = 5), tonsillitis (n = 5), and any event
(n = 21), all within 21 days postvaccination (Fig. 1). Sleep apnea
and tonsillitis occurred in 5 children who  were vaccinated on the
6–59, and 24–59 months of age relative to controls. *99% of inﬂuenza cases were
 RAD = reactive airway disease; SOB = shortness of breath; SOC = system organ class;
according to the Medical Dictionary for Regulatory Activities (MedDRA) along ﬁgure
(versus trivalent inactivated inﬂuenza vaccine [TIV], unvaccinated, within-cohort),
ys [21D], 42 days [42D] and 180 days [180D]). Events occurring at a signiﬁcantly
urring at a signiﬁcantly lower rate after LAIV are coded in blue. The within-cohort
 within the 21-day postvaccination interval only. Events occurring within 3 days of
 signiﬁcant, so only post-dose 1 results are shown. Events listed are those that were
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Fig. 2. Statistically signiﬁcant differences in PSDIs in LAIV recipients 24–35, 36–59, and 24–59 months of age relative to controls. PSDI = prespeciﬁed diagnosis of interest;
RAD  = reactive airway disease; SOB = shortness of breath; SOC = system organ class; URI = upper respiratory tract infection.
Individual medically attended events (MAEs) are grouped by organ class and medical term according to the Medical Dictionary for Regulatory Activities (MedDRA) along ﬁgure
rows.  Columns represent individual analyses which are organized by comparison group (versus trivalent inactivated inﬂuenza vaccine [TIV], unvaccinated, within-cohort)
and  time interval (21 days [21D],42 days [42D] and 180 days [180D]). Events in this ﬁgure are from all settings (clinic, emergency department, hospital) combined. Events
occurring at a signiﬁcantly higher rate after live attenuated inﬂuenza vaccine (LAIV) are coded orange and those occurring at a signiﬁcantly lower rate after LAIV are coded
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an  blue. The within-cohort analysis (self-control) columns are fewer in number beca
ccurring within 3 days of vaccination are not included in the ﬁgure. No events after
isted  are those that were signiﬁcant before the adjustment for multiple compariso
ame day as their preoperative examination for an elective ton-
illectomy and adenoidectomy procedure and were hospitalized
fter surgery with those diagnoses. Events in the hospital set-
ing that were signiﬁcantly decreased in LAIV recipients included
sthma/RAD within 21 and 42 days postvaccination in compar-
son to TIV-vaccinated controls and any event in comparison to
IV-vaccinated and within-cohort. The rate of any hospitalization
ithin 180 days postvaccination was signiﬁcantly decreased after
accination with LAIV in 3 comparisons; 1 versus unvaccinated con-
rols in the 24- to 35-month cohort and 2 versus TIV recipients for
ll ages and for the 24- to 35-month cohort (Fig. 2). For rare diag-
oses potentially related to WTI, 2 hospitalizations occurred in 1
ubject within 180 days postvaccination; the subject was admitted
n 2 occasions 41 and 44 days after LAIV vaccination for a diagno-
is of transverse myelitis; neither hospitalization was  judged to be
elated to vaccination.
.3. All medically attended events
Event rate comparisons are presented graphically in 2-
imensional heat maps (Figs. 1 and 2). Of 4696 incidence rate
omparisons, 304 (6%) yielded statistically signiﬁcant differences:
3 (1.8%) incidence rates were higher and 221 (4.7%) incidence rates
ere lower in LAIV recipients compared with controls.
Of the statistically signiﬁcant MAE  rate comparisons, 71%
ccurred in the clinic setting, and 23% and 6% occurred in ED and
ospital settings, respectively. Only 1 MAE  rate comparison was
igniﬁcantly increased among LAIV recipients relative to all 3 con-
rol groups. Urticaria (n = 30) occurred in LAIV recipients 36–59
onths of age in the clinic setting through 21 days postvacci-
ation compared with 18 and 13 events in TIV-vaccinated and
nvaccinated controls, respectively; in the within-cohort analy-
is, 11 events occurred during the reference period of 22–42 days.
rticaria events did not cluster within the 21-day period. Within 3
ays of LAIV vaccination there were 3 cases of urticaria, all in the
linic setting; the rate was not signiﬁcantly increased or decreased
n LAIV recipients relative to control groups. No anaphylaxis events
ccurred within 3 days postvaccination in LAIV recipients or any
ontrol group. One MAE  was signiﬁcantly decreased among LAIV
ecipients in the same age group and setting across all comparison
roups: asthma/RAD within 21 days postvaccination in all subjects
nd in subjects 36–59 months of age in the clinic setting.is analysis was performed within the 21-day postvaccination interval only. Events
nd dose were statistically signiﬁcant, so only post-dose 1 results are shown. Events
No PSDI comparison was signiﬁcantly increased among LAIV
recipients relative to all control groups. No statistically signiﬁ-
cant comparisons were due to SBI or rare diagnoses potentially
related to WTI. Eighty-two statistically signiﬁcant comparisons
were related to AW events; 4 occurred at higher rates after LAIV,
all of which were relative to unvaccinated controls (Figs. 1 and 2).
Asthma/RAD and the category of “any AW event” were decreased
among LAIV recipients in subjects 36–59 and 24–59 months of
age within 21 days postvaccination compared with all 3 control
groups.
Inﬂuenza was  increased after LAIV in 2 comparisons each versus
unvaccinated and TIV controls within 42 days postvaccination,
and decreased after vaccination with LAIV in the within-cohort
analysis in 2 comparisons. Of 193 inﬂuenza events among LAIV
recipients during the study period, 191 (99%) occurred during the
2009–2010 H1N1 inﬂuenza pandemic season. During this season,
2009 pandemic H1N1 vaccine was received by 34%, 62%, and 6% of
LAIV recipients, TIV-vaccinated, and unvaccinated controls, respec-
tively.
After the post hoc adjustment for multiple comparisons, 81
of 304 incidence rate comparisons remained statistically signiﬁ-
cant; 2 and 79 comparisons occurred at higher and lower rates,
respectively, after vaccination with LAIV (Table 3). Wheezing/SOB
occurred at increased rates after vaccination with LAIV in 2 com-
parisons versus unvaccinated controls in those 36–59 months
and 24–59 months of age within 180 days postvaccination; AW
events occurred at lower rates after LAIV compared with TIV-
vaccinated and unvaccinated controls in 42 comparisons. Events
occurring at decreased rates after LAIV included any respiratory
tract event, AW event, any event, asthma/RAD, cough, otitis media,
upper respiratory tract infection, viral syndrome, and wheez-
ing/SOB.
4. Discussion
Consistent with clinical trials [4,9], an analysis from the Vaccine
Adverse Events Reporting System in this same age population [10],
and postmarketing studies in older children [1],  no unexpected
clinically meaningful risks were associated with LAIV receipt in eli-
gible children 24–59 months of age. SAEs within 42 days postvacci-
nation were uncommon, and the most common diagnoses (trauma,
pneumonia, dehydration) are common causes for hospitalization
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Table  3
Statistically signiﬁcant differences in events after multiplicity adjustment in LAIV recipients 24–35, 36–59 and 24–59 months of age.
Event Control Risk period, days Setting LAIV rate Control rate RR* (95% CI) HR† (95% CI)
24–35 Months, decreased events
Any acute respiratory tract event Within 21 All 77.14 103.77 0.74 (0.66, 0.84) 0.89 (0.78, 1.02)
Any  asthma or wheezing event TIV 180 All 9.71 16.22 0.60 (0.53, 0.67) 0.61 (0.55, 0.69)
Any  asthma or wheezing event TIV 42 All 7.63 15.30 0.50 (0.38, 0.64) 0.53 (0.41, 0.69)
Asthma/RAD TIV 180 All 4.83 10.01 0.48 (0.41, 0.56) 0.50 (0.43, 0.58)
Asthma/RAD Unvax 180 All 4.89 7.30 0.67 (0.57, 0.79) 0.65 (0.55, 0.77)
Asthma/RAD TIV 21 Clinic 1.71 9.55 0.18 (0.09, 0.34) 0.19 (0.10, 0.38)
Asthma/RAD TIV 21 All 1.71 9.90 0.17 (0.08, 0.33) 0.18 (0.09, 0.36)
Asthma/RAD TIV 42 Clinic 2.59 9.96 0.26 (0.17, 0.39) 0.28 (0.19, 0.42)
Asthma/RAD TIV 42 All 2.59 10.23 0.25 (0.17, 0.37) 0.27 (0.18, 0.41)
Asthma/RAD Unvax 42 Clinic 2.59 8.03 0.32 (0.21, 0.49) 0.32 (0.21, 0.48)
Asthma/RAD Unvax 42 All 2.59 8.13 0.32 (0.21, 0.48) 0.31 (0.21, 0.47)
Viral  syndrome TIV 21 Clinic 0.00 5.20 0.00 (0.00, 0.10) NE
Viral  syndrome Unvax 21 Clinic 0.00 6.18 0.00 (0.00, 0.09) NE
Viral  syndrome TIV 42 Clinic 0.00 5.54 0.00 (0.00, 0.05) NE
Viral  syndrome Unvax 42 Clinic 0.00 5.97 0.00 (0.00, 0.04) NE
36–59  Months, increased events
Wheezing/SOB Unvax 180 All 4.60 3.45 1.33 (1.18, 1.51) 1.32 (1.17, 1.49)
36–59  Months, decreased events
Any acute respiratory tract event TIV 21 All 64.68 83.89 0.77 (0.71, 0.84) 0.83 (0.76, 0.90)
Any  acute respiratory tract event Within 21 All 64.68 89.81 0.72 (0.67, 0.78) 0.80 (0.74, 0.87)
Any  acute respiratory tract event TIV 42 All 73.64 86.93 0.85 (0.80, 0.90) 0.90 (0.85, 0.96)
Any  asthma or wheezing event TIV 180 All 8.28 15.95 0.52 (0.48, 0.56) 0.54 (0.50, 0.58)
Any  asthma or wheezing event Unvax 180 All 8.31 10.31 0.81 (0.74, 0.87) 0.80 (0.74, 0.86)
Any  asthma or wheezing event TIV 21 All 4.44 15.73 0.28 (0.22, 0.36) 0.28 (0.22, 0.37)
Any  asthma or wheezing event Unvax 21 All 4.44 11.15 0.40 (0.30, 0.52) 0.40 (0.30, 0.52)
Any  asthma or wheezing event TIV 42 All 6.18 17.03 0.36 (0.31, 0.43) 0.37 (0.32, 0.44)
Any  asthma or wheezing event Unvax 42 All 6.18 10.61 0.58 (0.49, 0.69) 0.58 (0.49, 0.70)
Any  event TIV 21 Clinic 73.09 94.74 0.77 (0.71, 0.83) 0.83 (0.76, 0.89)
Any  event Within 21 Clinic 73.08 97.40 0.75 (0.70, 0.81) 0.83 (0.76, 0.90)
Any  event TIV 42 Clinic 81.47 97.46 0.84 (0.79, 0.88) 0.89 (0.84, 0.93)
Asthma/RAD TIV 180 All 4.23 11.54 0.37 (0.33, 0.40) 0.38 (0.35, 0.42)
Asthma/RAD Unvax 180 All 4.26 7.42 0.57 (0.52, 0.64) 0.56 (0.51, 0.63)
Asthma/RAD TIV 21 Clinic 1.71 11.06 0.15 (0.10, 0.23) 0.15 (0.10, 0.22)
Asthma/RAD TIV 21 All 1.77 11.31 0.16 (0.10, 0.23) 0.15 (0.10, 0.22)
Asthma/RAD Unvax 21 Clinic 1.71 8.75 0.20 (0.13, 0.29) 0.19 (0.13, 0.29)
Asthma/RAD Unvax 21 All 1.77 8.82 0.20 (0.13, 0.30) 0.20 (0.13, 0.30)
Asthma/RAD TIV 42 Clinic 2.27 11.68 0.19 (0.15, 0.25) 0.20 (0.16, 0.26)
Asthma/RAD TIV 42 All 2.42 11.94 0.20 (0.16, 0.26) 0.21 (0.16, 0.27)
Asthma/RAD Unvax 42 Clinic 2.27 8.01 0.28 (0.22, 0.37) 0.28 (0.22, 0.36)
Asthma/RAD Unvax 42 All 2.42 8.07 0.30 (0.23, 0.38) 0.30 (0.23, 0.38)
Otitis  media Within 21 All 21.58 29.75 0.73 (0.63, 0.83) 0.87 (0.75, 1.00)
URI  Within 21 Clinic 25.13 34.49 0.73 (0.64, 0.83) 0.80 (0.70, 0.92)
URI Within 21 All 25.43 35.29 0.72 (0.64, 0.82) 0.79 (0.69, 0.91)
Viral  syndrome TIV 21 Clinic 0.06 5.96 0.01 (0.00, 0.05) 0.01 (0.00, 0.09)
Viral  syndrome Unvax 21 Clinic 0.06 5.96 0.01 (0.00, 0.05) 0.01 (0.00, 0.08)
Viral  syndrome TIV 42 Clinic 0.03 6.04 0.00 (0.00, 0.02) 0.01 (0.00, 0.04)
Viral  syndrome Unvax 42 Clinic 0.03 6.38 0.00 (0.00, 0.02) 0.00 (0.00, 0.04)
24–59  Months, increased events
Wheezing/SOB Unvax 180 All 4.89 3.91 1.25 (1.13, 1.38) 1.24 (1.12, 1.37)
24–59  Months, decreased events
Any acute respiratory tract event TIV 21 All 67.87 86.82 0.78 (0.73, 0.84) 0.84 (0.79, 0.90)
Any  acute respiratory tract event Within 21 All 67.88 93.39 0.73 (0.68, 0.78) 0.83 (0.77, 0.89)
Any  acute respiratory tract event TIV 42 All 77.08 89.69 0.86 (0.82, 0.90) 0.91 (0.87, 0.96)
Any  asthma or wheezing event TIV 180 All 8.65 16.02 0.54 (0.51, 0.57) 0.56 (0.52, 0.59)
Any  asthma or wheezing event Unvax 180 All 8.69 10.64 0.82 (0.76, 0.87) 0.80 (0.75, 0.86)
Any  asthma or wheezing event TIV 21 All 4.92 15.29 0.32 (0.26, 0.40) 0.33 (0.26, 0.41)
Any  asthma or wheezing event Unvax 21 All 4.92 11.51 0.43 (0.34, 0.53) 0.43 (0.34, 0.54)
Any  asthma or wheezing event TIV 42 All 6.55 16.57 0.40 (0.34, 0.45) 0.41 (0.36, 0.47)
Any  asthma or wheezing event Unvax 42 All 6.55 11.19 0.59 (0.50, 0.68) 0.58 (0.50, 0.68)
Any  event TIV 21 Clinic 76.45 98.42 0.78 (0.73, 0.83) 0.84 (0.78, 0.89)
Any  event Within 21 Clinic 76.46 99.95 0.76 (0.72, 0.82) 0.86 (0.80, 0.92)
Any  event TIV 42 Clinic 84.49 101.18 0.83 (0.80, 0.87) 0.88 (0.84, 0.92)
Asthma/RAD TIV 180 All 4.39 11.13 0.39 (0.36, 0.43) 0.41 (0.38, 0.44)
Asthma/RAD Unvax 180 All 4.42 7.39 0.60 (0.55, 0.65) 0.59 (0.54, 0.64)
Asthma/RAD TIV 21 Clinic 1.71 10.66 0.16 (0.11, 0.22) 0.16 (0.11, 0.22)
Asthma/RAD TIV 21 All 1.76 10.94 0.16 (0.11, 0.22) 0.16 (0.11, 0.22)
Asthma/RAD Unvax 21 Clinic 1.71 8.34 0.21 (0.14, 0.29) 0.20 (0.14, 0.29)
Asthma/RAD Unvax 21 All 1.76 8.39 0.21 (0.15, 0.29) 0.21 (0.15, 0.29)
Asthma/RAD TIV 42 Clinic 2.36 11.22 0.21 (0.17, 0.26) 0.22 (0.18, 0.27)
Asthma/RAD TIV 42 All 2.47 11.48 0.21 (0.17, 0.26) 0.22 (0.18, 0.27)
Asthma/RAD Unvax 42 Clinic 2.36 8.01 0.29 (0.24, 0.37) 0.29 (0.23, 0.36)
Asthma/RAD Unvax 42 All 2.47 8.09 0.31 (0.25, 0.38) 0.30 (0.24, 0.37)
Cough TIV 21 Clinic 5.19 8.76 0.59 (0.47, 0.74) 0.63 (0.50, 0.81)
Cough  TIV 21 All 5.36 9.18 0.58 (0.47, 0.73) 0.62 (0.49, 0.79)
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Table  3 (Continued)
Event Control Risk period, days Setting LAIV rate Control rate RR* (95% CI) HR† (95% CI)
Otitis media Within 21 Clinic 21.86 28.88 0.76 (0.67, 0.85) 0.92 (0.81, 1.04)
Otitis  media Within 21 All 22.35 30.40 0.74 (0.65, 0.83) 0.89 (0.79, 1.01)
URI TIV 21 All 27.31 35.27 0.77 (0.70, 0.86) 0.85 (0.76, 0.94)
URI Within 21 Clinic 26.64 37.28 0.71 (0.64, 0.79) 0.81 (0.72, 0.90)
URI  Within 21 All 27.31 38.34 0.71 (0.64, 0.79) 0.80 (0.72, 0.90)
URI TIV  42 Clinic 31.52 37.40 0.84 (0.78, 0.91) 0.90 (0.84, 0.97)
URI  TIV 42 All 32.30 38.43 0.84 (0.78, 0.90) 0.90 (0.84, 0.97)
Viral  syndrome TIV 21 Clinic 0.04 5.76 0.01 (0.00, 0.04) 0.01 (0.00, 0.07)
Viral  syndrome Unvax 21 Clinic 0.04 6.02 0.01 (0.00, 0.04) 0.01 (0.00, 0.06)
Viral  syndrome TIV 42 Clinic 0.02 5.91 0.00 (0.00, 0.02) 0.00 (0.00, 0.03)
Viral  syndrome Unvax 42 Clinic 0.02 6.27 0.00 (0.00, 0.02) 0.00 (0.00, 0.03)
LAIV = live attenuated inﬂuenza vaccine; RAD = reactive airway disease; HR = hazard ratio; RR = relative risk; SOB = shortness of breath; TIV = trivalent inactivated inﬂuenza
vaccine; Unvax = unvaccinated; URI = upper respiratory tract infection. Event rates were calculated per 1000 person-months.
* Fisher exact test.
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n children 1–4 years of age [11]. Anaphylaxis after LAIV vaccina-
ion was not observed, and urticaria within 3 days postvaccination
as uncommon.
Because of the exploratory nature of this study and the lack
f formal hypothesis testing, no corrections were made for multi-
le comparisons in the primary analysis. Among the large number
f comparisons, one would expect many statistically signiﬁcant
esults by chance alone. The differences in the nonrandomized
omparison groups that remained despite matching likely con-
ributed to events occurring at higher rates after vaccination with
AIV in comparison with unvaccinated controls, as well as to
vents occurring at lower rates after LAIV in comparison with
IV-vaccinated controls. Given the warnings against use of LAIV
n individuals with underlying medical conditions, it is likely that
IV-vaccinated controls had a poorer health status relative to LAIV
ecipients, even after exclusion of individuals with identiﬁable
igh-risk underlying medical conditions. It also appears likely that,
espite matching, there were underlying differences between LAIV
ecipients and unvaccinated controls, with unvaccinated controls
eing less likely to access healthcare overall. These patterns have
een observed previously [1,12].  Given the underlying biases for
he comparisons to TIV-vaccinated and unvaccinated controls, the
ost valuable comparison appears to be the within-cohort analy-
is, because it controls for many covariates that are uncontrolled
mong the disparate groups. Only 7 of the 83 statistically sig-
iﬁcant events that were increased after LAIV were found in the
ithin-cohort analysis, and no comparison in the within-cohort
nalyses that was increased after LAIV remained statistically signif-
cant after post hoc adjustment for multiple comparisons. Twelve
omparisons in the within-cohort analyses remained statistically
igniﬁcant after adjustment and all showed decreased rates of oti-
is media, upper respiratory tract infection, or any ART event after
accination with LAIV.
Only 1 MAE  occurred at a higher rate after LAIV in compari-
on to all 3 control groups: urticaria in those 36–59 months of age
ithin 21 days postvaccination in the clinic setting. This repre-
ents a biologically plausible postvaccination event [13] for LAIV
nd occurred at a potential vaccine-attributable rate of 5–8 events
er 10,000 subjects. However, the increase may  also have been due
o chance alone because this same ﬁnding was not found in those
4–35 months of age in this study or in those 5–8, 9–17, or 18–49
ears of age in similar safety studies of LAIV [1,2] or within 10 days
f vaccination in an integrated analysis of randomized studies of
AIV involving safety data collected from 15,000 LAIV recipients [9].
fter correcting for multiple comparisons, the MAE of urticaria was
o longer statistically signiﬁcant. In addition, the rate of urticaria
ithin 3 days postvaccination, which would represent the more
oncerning immediate hypersensitivity reaction, did not occur ata  signiﬁcantly greater rate after vaccination with LAIV compared
with any control group.
Of the 193 LAIV-vaccinated subjects with an MAE  of inﬂuenza,
191 (99%) events occurred during the 2009–2010 H1N1 pandemic
season. The seasonal inﬂuenza vaccine would not be expected
to protect against the 2009 H1N1 pandemic strain. Increased
inﬂuenza cases after LAIV vaccination in comparison to those
unvaccinated likely results from the health-seeking bias described
above, whereas increases in inﬂuenza cases after LAIV vaccination
in comparison to TIV likely represent increased utilization of the
monovalent H1N1 pandemic vaccine among seasonal TIV recipi-
ents. The different rates of H1N1 vaccination among LAIV and TIV
recipients may  result from the recommendation to separate H1N1
LAIV and seasonal LAIV administration by approximately 1 month.
As H1N1 LAIV was the ﬁrst 2009 H1N1 vaccine available for chil-
dren, providers would have been more likely to administer H1N1
LAIV and seasonal TIV to previously unvaccinated children to avoid
administering the 2 live vaccinations concurrently. As a result, sea-
sonal LAIV recipients would have been more likely to be those not
seeking H1N1 vaccination, consistent with the disparity observed
in the current study.
Because LAIV has been associated with an increase in wheezing
MAEs in children <24 months of age [3,4], a comprehensive anal-
ysis of AW events was conducted. As noted above, children with
a prior diagnosis of asthma were excluded from the analysis. AW
events decreased after vaccination with LAIV in each setting and
in all settings combined within 21, 42, and 180 days postvaccina-
tion in all age strata and in comparison to all control groups. Only
4 of 82 (5%) AW comparisons occurred at higher rates after LAIV in
comparison to those unvaccinated; 2 remained statistically signif-
icant after adjusting for multiple comparisons. Consistently lower
rates of wheezing and other respiratory events after LAIV may  be
due to residual confounding, or could potentially be due to protec-
tion against general viral illness via innate immunity, such as that
induced by interferon [14,15].  Reductions in wheezing and viral ill-
ness after vaccination have been seen in other LAIV studies [16,17].
Strengths of this study include the large sample size, the use
of multiple controls, and the abilities to capture events after
real-world use of LAIV over multiple inﬂuenza seasons and to
examine all MAEs for any diagnosis. The nonrandomized design is
likely responsible for many of the differences between comparison
groups; however, use of multiple groups helped clarify some dif-
ferences. Furthermore, this study design did not permit systematic
determination of whether an observed event resulted from a preex-
isting condition; evaluations of medical history were only feasible
for select subjects through detailed chart review. Finally, it is impor-
tant to note that inferences drawn from the evaluated KP members
may  not be completely generalizable to the overall US  population.
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. Conclusion
In summary, in this study of more than 28,000 unique LAIV
ecipients 24–59 months of age, SAEs and hospitalizations after
accination with LAIV were uncommon, and no pattern of MAEs,
ncluding MAEs related to asthma or wheezing, suggested a clin-
cally signiﬁcant safety signal with LAIV. The results of this study
re consistent with clinical studies [3,18,19], reports to the Vac-
ine Adverse Events Reporting System in the years after the initial
pproval of LAIV [20], and postmarketing safety studies in older
hildren [1],  which demonstrated no signiﬁcant adverse outcomes
fter receipt of LAIV by eligible children 2–17 years of age.
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